SEC Form 4 · accession 0001193125-26-389550
Metagenomi Therapeutics, Inc. · MGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurence Reid
Director
Period of report
Sep 9, 2026
Accepted (ET)
Sep 11, 2026 · 7:51 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001785279
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 9, 2026 | P | 19,883 | $1.17 | A | 19,883 | D | |
| Common Stock | Sep 9, 2026 | P | 117 | $1.18 | A | 20,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.165 to $1.175. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request.